The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 23, 2025
Filed:
Aug. 13, 2019
Applicant:
Aiviva Biopharma, Inc., Las Vegas, NV (US);
Inventors:
Gerald Woodrow Devries, San Clemente, CA (US);
Diane Tang-Liu, Las Vegas, NV (US);
Assignee:
AIVIVA BIOPHARMA, INC., Las Vegas, NV (US);
Primary Examiner:
Int. Cl.
CPC ...
A61P 27/02 (2006.01); A61K 31/404 (2006.01); A61K 31/44 (2006.01); A61K 31/4418 (2006.01); A61K 31/4439 (2006.01); A61K 31/47 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61P 15/00 (2006.01); A61P 17/00 (2006.01); A61P 19/04 (2006.01); A61P 29/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/506 (2013.01); A61K 31/404 (2013.01); A61K 31/44 (2013.01); A61K 31/4418 (2013.01); A61K 31/4439 (2013.01); A61K 31/47 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5025 (2013.01); A61P 15/00 (2018.01); A61P 17/00 (2018.01); A61P 19/04 (2018.01); A61P 27/02 (2018.01); A61P 29/00 (2018.01);
Abstract
A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, associated with angiogenesis and fibrosis. The pharmaceutical composition includes a multi-target inhibitor, multi-phase modulator, or multi-kinase inhibitor, such as axitinib, nintedanib, pirfenidone, riociguat, sorafenib, sunitinib, lenvatinib, regorafenib, ponatinib, or pazopanib.